$2.470
-0.105 (-4.26%)Zum Schluss
XTLB-News
XTLB-Events
XTL Biopharmaceuticals Acquires 100% of Psyga Bio
XTL Biopharmaceuticals announced that it has entered into a definitive share purchase agreement to acquire 100% of the issued and outstanding share capital of Psyga Bio. Psyga operates a licensed, GMP-ready pharmaceutical manufacturing facility designed for the cultivation, extraction, isolation, formulation and production of pharmaceutical-grade botanical and synthetic psilocybin, Ibogaine and other psychedelic active pharmaceutical ingredients, in accordance with applicable international pharmaceutical manufacturing standards. Pursuant to the purchase agreement, the company will acquire from the current shareholder of Psyga all of the issued and outstanding share capital of Psyga on a fully diluted basis in exchange for the issuance by the company to the current shareholders of Psyga, by way of a private placement, of such number of ADSs of the company representing, immediately after such issuance, 40% of the issued and outstanding share capital of the company. No cash consideration will be paid by the company at the closing of the transaction. In addition, as part of the transaction, the current shareholders of Psyga will be entitled to receive additional ADSs representing 10% of the issued and outstanding share capital of the company as of the effective date of the purchase agreement upon the achievement of each of three milestones: the commencement of at least three human clinical trials from Psyga's pipeline within twelve months following closing, the successful achievement of targets in at least two human clinical trials from Psyga's pipeline within thirty-six months following closing, and the commencement of the development of Ibogaine-based products, triggered by the execution of a binding commercialization agreement and/or development partnership agreement with a third-party pharmaceutical, biotechnology or life sciences company for the commercialization, licensing, development and/or co-development of Ibogaine-based products based on the Company's applicable regulatory licenses, on arm's-length terms.
Beyond Air Terminates Transaction with XTL Biopharmaceuticals
Beyond Air (XAIR) announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals (XTLB) relating to Beyond Air's NeuroNOS subsidiary has been terminated. The companies entered into a letter of intent in January 2026 regarding a potential transaction in which XTL would acquire Beyond Air's majority ownership interest in NeuroNOS Ltd. The letter of intent expired on March 9, 2026, in accordance with its terms, and the parties did not enter into a definitive agreement. "While the proposed transaction will not proceed, Beyond Air remains committed to maximizing the value of the NeuroNOS platform," said Steve Lisi, CEO. "We continue to believe NeuroNOS represents a compelling opportunity based on its proprietary small-molecule platform and development programs targeting neurological disorders and oncology." Beyond Air will continue to evaluate strategic alternatives for NeuroNOS and remains focused on advancing its core nitric oxide platform and LungFit programs
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk
XTL Biopharmaceuticals announced that it has received a letter from Nasdaq, dated February 25, notifying the company of the staff's belief, based upon its review of the company and pursuant to Nasdaq Listing Rule 5101, that the company is a "public shell", and that continued listing of the company's American depositary shares is no longer warranted. The company intends to request a hearing to appeal the delisting process before a Nasdaq Hearings Panel. A Hearing request will stay the suspension of the ADSs and delisting pending the Panel's decision. The letter stated that the staff believes the company no longer has an operating business, citing the company's prior public disclosure that its wholly owned subsidiary, The Social Proxy, had filed a formal application with the competent Israeli court for the commencement of insolvency proceedings and that on February 22, the court ordered The Social Proxy's liquidation and the appointment of a trustee for the insolvency proceedings. The staff noted that the company's purported shell status could lead to the ADSs being subject to market abuses and other violative conduct and that purchasers of the company's securities do not know what the operating business of the company will be in the future.
XTL Biopharmaceuticals Plans to Acquire 85% of NeuroNOS Shares
XTL Biopharmaceuticals (XTLB) announced that it is working to close the acquisition of 85% of the shares of NeuroNOS from Beyond Air (XAIR) following the execution of the binding letter of intent on January 13 and has already scheduled a shareholders meeting for February 17 to approve a private placement of up to $2M. Management of the company believes that the completion of the proposed transaction to acquire 85% of the shares of NeuroNOS as well as the private placement, will remedy its deficiency under Nasdaq Listing Rule 5550 to maintain a minimum of $2.5M in stockholders' equity. The company is currently working to submit to Nasdaq a plan to regain compliance with this Nasdaq Listing Rule. However, there can be no assurance at this point that the proposed acquisition will close in a timely manner or at all or that shareholders will approve the private placement in a timely manner or at all, nor can there be any assurance that Nasdaq will approve the company's plan, that the company will regain compliance with the stockholders' equity rule, or that the company will maintain compliance with any of Nasdaq's other listing rules.
XTL Biopharmaceuticals Acquires 85% of Beyond Air's NeuroNOS
XTL Biopharmaceuticals (XTLB) announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air (XAIR), a biotechnology company pioneering disease-modifying therapeutics targeting the core pathophysiology of Autism Spectrum Disorder and neuro-oncology. NeuroNOS's drug development platform is based on a proprietary family of small molecules engineered to cross the blood-brain barrier and precisely target diseases associated with nitric oxide abnormalities in the brain. Preclinical studies have demonstrated that the platform addresses core pathological mechanisms rather than merely alleviating symptoms, validated NO dysregulation has been observed in both autism patients and brain cancer patients, establishing NO regulation as a disease-modifying therapeutic target across multiple indications. The company has already secured two FDA Orphan Drug Designations for Phelan-McDermid Syndromeand Glioblastoma. These designations provide seven years of market exclusivity upon approval, tax credits for clinical trial costs, expedited regulatory review, and enhanced FDA engagement. XTL will acquire 85% of NeuroNOS for consideration including 19.9% of XTL's issued share capital, $1M in cash, and milestone-based contingent payments totaling up to $32.5M. The milestone structure includes clinical development payments of up to $5.5 million to Beyond Air, commencing from the Phase 1 clinical trial through NDA submission to the FDA. In addition, commercial milestone payments of up to $26M are payable upon achieving product sales targets. Both Beyond Air and XTL are dedicated to bringing the NeuroNOS product for the treatment of autism to market as soon as possible. NeuroNOS, previously a subsidiary of Beyond Air, will now serve as XTL's flagship platform for autism and neuro-oncology therapeutics.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.